AHZ last traded at $0.074.
Turvey paid $19,999.98 to convert the options into 333,333 shares, increasing his direct and indirect interest up to 2,775,535 shares.
He retains 333,334 of the same unlisted options exercisable at $0.06 and expiring 18 May 2017 as well as 500,000 unlisted options exercisable at $0.27 that expire on 16 December 2018.
Admedus recently raised $12 million through a heavily oversubscribed placement to boost sales and advance its regenerative tissue product development and immunotherapy programs.
It will also undertake a 1 for 7 non-renounceable pro-rata offer of shares priced at $0.07 to raise up to $16 million.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.